Document Detail

Evaluation and treatment of hepatitis C in patients with human immunodeficiency virus.
MedLine Citation:
PMID:  23038477     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVES: The rate of treatment of hepatitis C virus (HCV) infection in human immunodeficiency virus-hepatitis C virus (HIV-HCV) co-infected patients remains historically low. We undertook a retrospective study to review our treatment rate and factors that have negatively influenced this rate. In those treated, we reviewed outcomes and compared results with prior studies.
METHODS: A total of 233 patients infected with HIV and HCV were followed for 7 years in the infectious diseases (ID) clinic of East Carolina University. Proper follow-up evaluation was determined based on the presence of HCV polymerase chain reaction viral load and genotype testing. The number of patients treated, response to treatment, and reason for no treatment were determined by chart review.
RESULTS: Of 233 patients with positive HCV serology, 48 were excluded due to undetectable HCV viral load. Of the remaining 185 patients, 142 (77%) were evaluated by testing for HCV viral load and genotype, but only 112 of those who were followed up in the clinic regularly were considered eligible for therapy. Fourteen of 112 (12.5%) of patients underwent treatment and only 1 in 14 (7%) attained sustained virological response (SVR). Of the patients tested, 96% had HCV genotype 1, and 81% were African American.
CONCLUSIONS: The majority of our HIV-HCV co-infected patients received a proper HCV evaluation, but only 12.5% were offered therapy. Of those treated, only one patient achieved SVR. The higher proportion of genotype 1 and African American patient population are considered the main reasons for the low SVR. Low SVR rate, high rate of adverse effects, and the unique demography of our patient population have been the main reasons for the lower treatment rate.
Gentiana Bakaj; Tatsiana Valasiuk; Rupali Prabhukhot; Dawd Siraj
Related Documents :
23199497 - Public health issues of hepatitis c virus infection.
24367227 - Rifaximin in the treatment of hepatic encephalopathy.
24829647 - Letter to hajiani e, hashemi sj, masjedizadeh a, shayesteh aa, jalali f. genotypic anal...
24373087 - Hbeag-positive chronic hepatitis b: why do i treat my patients with pegylated interferon?
23846587 - First molecular typing of cryptococcemia-causing cryptococcus in central-west brazil.
24983017 - Prevention and control of hepatitis c in rhode island.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Southern medical journal     Volume:  105     ISSN:  1541-8243     ISO Abbreviation:  South. Med. J.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0404522     Medline TA:  South Med J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  500-3     Citation Subset:  AIM; IM    
From the Departments of Internal Medicine and Infectious Diseases, East Carolina University/Pitt County Memorial Hospital, Greenville, North Carolina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of body mass index on postoperative complications after rectal resection for carcinoma.
Next Document:  Occurrence of vitamin d deficiency in pediatric patients at high risk in west virginia.